XRTX - XORTX jumps over 100% after early encouraging data for rare disease therapy

• Nano-cap pharma XORTX Therapeutics ( NASDAQ: XRTX ) surged ~103% on above average volume in the pre-market Wednesday after the company announced encouraging results for the company’s oxypurinol formulation from a pharmacokinetics bridging study.
• The trial XRX-OXY-101 was the Part 1 of the three-part pharmacokinetics bridging study conducted ahead of a late-stage phase 3 registration trial in autosomal dominant polycystic kidney disease (“ADPKD”), a rare disease that is estimated to affect more than 10M globally.
• According to topline data, two versions of XORTX’s ( XRTX ) oxypurinol formulation was found to have a substantial increase in oral bioavailability compared to a control, the company said.
• In addition, the oral administration of oxypurinol showed a clean safety and pharmacologic profile with no drug related adverse or serious adverse events, XORTX ( XRTX ) added.

For further details see: